Results below 95% warrant concern
Before treatment, tell our team if you: Are pregnant, breastfeeding, or trying to become pregnant Have a personal or family history of medullary thyroid cancer Have Multiple Endocrine Neoplasia syndrome type 2 Have a history of pancreatitis Have gallbladder disease Have kidney disease or dehydration concerns Have diabetes or take insulin/sulfonylureas Have severe gastrointestinal disease or gastroparesis Take medications that may interact with treatment Have had bariatric surgery or major digestive issues Are using any other weight loss medication Patients should also be careful about the unapproved GLP-1 drugs marketed for weight loss
Rotating between these three sites reduces the risk of lipohypertrophy, a condition where repeated injections in the same spot cause localized fat deposits or indentations
For compounded tirzepatide, understanding reconstitution procedures and proper mixing ratios ensures consistent dosing and sterility
Understanding the differences between GLP-1 medications helps you have a more informed conversation with your healthcare provider
No published randomized, controlled human clinical trial has evaluated ProHealth BPC-157 - or any commercially available BPC-157 supplement - as a finished formulation